Hims & Hers Health, Inc. (HIMS)

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. The company was formerly known as Hims, Inc. and changed its name to Hims & Hers Health, Inc. in January 2021. The company was founded in 2017 and is based in San Francisco, California.

Ticker
HIMS
Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Market cap
$4.35B
52-week range
$13.74 - $40.99

Valuation

Share price
$18.56 (close of Nov 16, 2026)
P/E (TTM)
-22.63x
Price to book
12.25x
Price to free cash flow
529.15x
Enterprise value
$5.20B
Book value per share
$1.52

Price performance

PeriodChange
1 day-5.93%
5 days-19.09%
1 month-33.88%
3 months-34.07%
6 months-25.91%
Year to date-42.84%
1 year-49.81%
3 years+140.73%
5 years+126.62%
All time+89.39%

Short interest

As of
Oct 30, 2026
Short % of float
26.47%
Shares short
51.66M
Days to cover
5.84
Change since prior report
-3.40%
Source
FINRA consolidated short interest

Members of Congress who disclosed HIMS trades

Lisa McClain

Super investors holding HIMS

Ken Griffin (Citadel) · Ray Dalio (Bridgewater Associates)

Profitability and growth

Return on equity
23.73%
Return on invested capital
6.36%
Return on assets
5.96%
Return on capital employed
6.03%
Gross margin
73.84%
Net margin
5.47%
EBITDA margin
6.82%
Revenue growth
59.00%
Net income growth
1.85%
Free cash flow growth
-71.05%

Cash flow and balance sheet

Free cash flow yield (TTM)
0.19%
Current ratio
0.92x
Net debt to EBITDA
-6.80x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$2.35B
Cost of revenue
$614.26M
Gross profit
$1.73B
EBITDA
$160.12M
Net income
$128.37M
Earnings per share
$0.57
Shares outstanding
224.96M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$2.35B$1.73B$128.37M$0.57
2024-12-31$1.48B$1.17B$126.04M$0.58
2023-12-31$872.00M$714.95M-$23.55M-$0.11
2022-12-31$526.92M$408.72M-$65.68M-$0.32
2021-12-31$271.88M$204.49M-$107.66M-$0.58
2020-12-31$148.76M$109.45M-$18.11M-$0.51
2019-12-31$82.56M$44.60M-$72.06M-$2.07

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3173.84%5.47%23.73%6.36%
2024-12-3179.45%8.54%26.44%12.68%
2023-12-3181.99%-2.70%-6.84%-8.32%
2022-12-3177.57%-12.46%-21.07%-21.66%
2021-12-3175.22%-39.60%-32.17%-32.90%
2020-12-3173.58%-12.18%--
2019-12-3154.03%-87.29%--

Cash and debt by year

Period endCashDebt
2025-12-31$577.49M$972.58M
2024-12-31$300.25M-
2023-12-31$220.98M-
2022-12-31$179.63M-
2021-12-31$247.27M-
2020-12-31$100.21M-
2019-12-31$1.51M-

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$57.41M$135.24M
2024-12-31$198.28M$92.32M
2023-12-31$46.98M$66.08M
2022-12-31-$33.73M$42.82M
2021-12-31-$34.41M$67.21M
2020-12-31-$2.48M$5.83M
2019-12-31-$74.87M$8.03M

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-11-09Sep 2026$0.07
2026-08-10Jun 2026-$0.07
2026-05-11Mar 2026$0.04
2026-02-23Dec 2025$0.02
2025-11-03Sep 2025$0.09
2025-08-04Jun 2025$0.18
2025-05-05Mar 2025$0.12
2025-02-24Dec 2024$0.12

Filings and sources

Company website
hims.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Haleon plc (HLN) · Viatris Inc (VTRS) · Zoetis Inc. (ZTS) · Teva Pharmaceutical Industries Ltd (TEVA) · McKesson Corp (MCK) · Cencora, Inc. (COR) · Cardinal Health Inc (CAH) · Novo Nordisk A S (NVO)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades